問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Principal Investigator

Principal Investigator


Taipei Veterans General Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Taipei Medical University Hospital (在職)

Division of Thoracic Medicine

Division of Hematology & Oncology

Digestive System Department

Division of General Internal Medicine

Taipei WanFang Hospital (Managed by Taipei Medical Univeristy)

Division of Thoracic Medicine

更新時間：2023-09-19

邱昭華Chiu, Chao-Hua
  • Principal Investigator
  • Clinical Trial Experience (year) 18 years

  • chaohuachiu@tmu.edu.tw

Recruiting Trial

86Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

邱昭華

List

176Cases

2017-03-14 - 2025-05-13

Phase II

An Open-Label, Multicenter, Global Phase 2 Basket Study of for the Treatment of Patients with Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Condition/Disease

    Locally Advanced or Metastatic Solid Tumors that Entrectinib Harbor NTRK1/2/3, ROS1, or ALK Gene Rearrangements

  • Test Drug

    Entrectinib

Participate Sites
5Sites

Recruiting3Sites

Terminated2Sites

羅永鴻
Taipei Veterans General Hospital

2015-06-01 - 2018-12-31

Phase III

A Phase III open-label, multicenter trial of avelumab (MSB0010718C) versus docetaxel in subjects with non-small cell lung cancer that has progressed after a platinum-containing doublet

  • Condition/Disease

    NSCLC

  • Test Drug

    avelumab

Participate Sites
6Sites

Terminated6Sites

楊政達
Linkou Chang Gung Medical Foundation

2011-10-01 - 2015-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2011-11-01 - 2016-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Not yet recruiting5Sites

Terminated1Sites

2008-10-01 - 2010-12-31

Phase II/III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2018-03-01 - 2019-09-30

Others

Phase 1b/2 Safety, Pharmacokinetic, and Efficacy Study of G1T38 in Combination with Osimertinib in Patients with EGFR Mutation-Positive Metastatic Non-Small Cell Lung Cancer (NSCLC)

  • Condition/Disease

    Non-Small Cell Lung Cancer, NSCLC

  • Test Drug

    G1T38

Participate Sites
10Sites

Terminated9Sites

2022-04-15 - 2023-10-11

Phase I

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Recruiting4Sites

2008-10-31 - 2012-10-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2013-07-01 - 2021-06-30

Phase II

A Randomized, Controlled Phase 2 Study Evaluating LY2875358 plus Erlotinib versus Erlotinib as First-Line Treatment in Metastatic Non–Small Cell Lung Cancer Patients with Activating EGFR Mutations Who Have Disease Control after an 8-Week Lead-In Treatment with Erlotinib

  • Condition/Disease

    Non–Small Cell Lung Cancer

  • Test Drug

    LY2875358

Participate Sites
5Sites

Terminated5Sites

夏德椿
China Medical University Hospital

Division of Thoracic Medicine

2022-05-01 - 2023-02-23

Others

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Recruiting2Sites

1 14 15 16 17 18
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB